Sanofi-Aventis settles with generics makers
PARIS, France French drug maker Sanofi-Aventis has reached a settlement with two generic drug makers over their versions of two of its drugs.
Barr Labs and Teva make generic versions of the allergy drugs Allegra (fexofenadine hydrochloride), and Barr makes a generic Nasacort (triamcinolone). Under the settlement, the two companies will pay Sanofi royalties in exchange for patent rights allowing them to sell cheaper versions of the drugs. Sanofi would not disclose how much money the two companies would pay.
Teva is in the process of buying Barr.
FDA, SciClone meet agreement on distribution of melanoma treatment
NEW YORK The Food and Drug Administration has reached an agreement with a drug maker on the design of a phase 3 trial of a skin cancer drug.
SciClone Pharmaceuticals announced Monday that it had reached the agreement with the agency concerning the drug thymalfasin, which it sees as a potential treatment for stage 4 melanoma.
“Patients suffering from stage 4 melanoma have very few treatment options available,” SciClone chief medical officer Israel Rios said in a statement. “Based on the positive data from an earlier phase 2 trial, thymalfasin could provide new treatment modalities for this high unmet medical need.”
The drug, if approved, will be sold under the brand name Zadaxin. The full name of its active ingredient is thymosin alpha 1.
Teva releases generic version of AstraZeneca’s Pulmicort
NORTH WALES, Pa. The world’s largest maker of generic drugs has introduced a generic version of AstraZeneca’s Pulmicort Respules.
Teva announced Wednesday that it had launched budesonide inhalation suspension, a treatment for asthma, in 0.25-mg-per-2-milliliters and 0.5-mg-per-2-milliliter strengths.